Journal article icon

Journal article

Reprogrammed SimCells for antimicrobial therapy

Abstract:
Antimicrobial resistance (AMR) is a critical global health challenge. In this study, we developed a platform based on chromosome-free and nonreplicating simple cells (SimCells, size 1 to 2 µm) and mini-SimCells (size 100 to 400 nm) for targeted pathogen elimination. Engineered with surface-displayed nanobodies, SimCells and mini-SimCells selectively bind bacteria expressing specific antigens (e.g., OmpA in Escherichia coli). The selective interactions facilitate close SimCell-pathogen proximity, enabling two antimicrobial mechanisms: direct injection of toxic effectors into bacterial cytoplasm via a heterologous expression of type VI secretion system (T6SS), and enzymatic conversion of aspirin into catechol by engineered salicylate hydroxylase, leading to sustained local production of hydrogen peroxide (H2O2). Our results demonstrate that both reprogrammed SimCells and mini-SimCells can eliminate target E. coli with high specificity and efficiency. Multidose reprogrammed mini-SimCell treatment led to a 103-fold selective reduction of targeted bacteria in mixed microbial communities, with minimal disruption to nontarget bacteria. We demonstrate that reprogrammed mini-SimCells, engineered with nanobody targeting outer membrane protein OmpA of the clinically relevant multidrug-resistant pathogen E. coli ST131, achieved elimination efficiencies over 97% at 24 and 48 h. This modularized "plug-and-play" antimicrobial platform provides a highly specific, efficient, and adaptable solution for combating diverse AMR pathogens.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1073/pnas.2517118123

Authors

More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Engineering Science
Role:
Author
More by this author
Institution:
University of Oxford
Research group:
Oxford Suzhou Centre for Advanced Research
Role:
Author
More by this author
Institution:
University of Oxford
Research group:
Oxford Suzhou Centre for Advanced Research
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Pathology Dunn School
Role:
Author


More from this funder
Funder identifier:
https://ror.org/029chgv08
Grant:
209397/Z/17/Z
More from this funder
Funder identifier:
https://ror.org/0472cxd90
Grant:
787932
More from this funder
Funder identifier:
https://ror.org/0439y7842
Grant:
EP/Y014073/1
M002403/1
More from this funder
Funder identifier:
https://ror.org/00cwqg982
Grant:
BB/T008784/1


Publisher:
National Academy of Sciences
Journal:
Proceedings of the National Academy of Sciences More from this journal
Volume:
123
Issue:
12
Article number:
e2517118123
Place of publication:
United States
Publication date:
2026-03-17
Acceptance date:
2026-02-18
DOI:
EISSN:
1091-6490
ISSN:
0027-8424
Pmid:
41843676


Language:
English
Pubs id:
2390888
Local pid:
pubs:2390888
Source identifiers:
W7138127367
Deposit date:
2026-03-31
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP